BeiGene | Briefing, News, Analysis, Research, Data

BeiGene

BeiGene is a life sciences biotechnology company.

BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Specialty Pharma

Founded

Oct 28, 2010

HQ location

Beijing, China

Legal name

BeiGene, Ltd.

Website

http://www.beigene.com

nannan.jia@beigene.com

Employees

501-1000

All
News
Analysis
Research

Briefing Jan 10, 2022 05:09 PM · Industrials | Financials | Automotive

Yu Minhong responded to New Oriental's business reduction, dismissal and other issues: about 50000 employees remained

Briefing Jan 06, 2022 04:29 PM · Real Estate | Financials | Technology

Zhejiang Jiaxing further liberalizes settlement conditions

In depth

Herbal plants in the beakers are observed for pharmaceutical experiment. Image credit: Chuttersanp/Unsplash

Healthcare

China’s Healthcare ETF: The Next Limelight

Amid the COVID-19 pandemic, the Chinese Shenzhen stock market was the only market with a positive growth rate (in Q1 2020). In the meantime, China’s healthcare industry has got more of a spotlight on the global stage.

May 10, 2020 11:33 PM

Briefing Jan 05, 2022 11:24 AM · Healthcare

54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare

Briefing Dec 29, 2021 07:39 AM · Technology | Consumer Discretionary | Healthcare

During the year, the first day earnings of 7 new shares exceeded 100000 yuan, and 14 new shares were broken on the first day of listing

Research

Healthcare, Technology, Consumer Staples

WIA2020 | Rising Tech Stars 2020: Global & China's 100

Dec 09, 2020 09:57 AM

Research

Healthcare

WIA2020 | Next 50 in Global Tech: Healthcare

Dec 09, 2020 09:39 AM

Research

Real Estate, Industrials, Financials

Tech for Global, Globalization Footprints of the Established and the New

May 29, 2020 08:30 PM

Research

Real Estate, Industrials, Financials

Low-Carbon Industry Expansion - Key Studies From Chinese Companies

May 28, 2020 12:40 PM

Briefing Dec 26, 2021 04:18 PM · Industrials | Financials

Baiji Shenzhou: 497 million yuan of excess placement funds will be included in the Securities Investor Protection Fund

Briefing Dec 13, 2021 07:19 PM · Financials | Technology | Healthcare

South Network Technology: 44100 winning lots

Briefing Dec 10, 2021 04:48 PM · Healthcare

Baiji Shenzhou announced that bevacizumab injection is a biological analogue of pubeshi ® Commercial listing in China

Briefing Dec 07, 2021 07:39 PM · Financials | Technology | Healthcare

Shengxin lithium energy: the design capacity of sabixing Lithium Tantalum mine project is expected to be 900000 tons / year of ore processing capacity

Healthcare

Hillhouse Capital Invested Heavily in Chinese Stocks in Q3 2021

The SEC disclosed Hillhouse Capital's secondary market exposure on November 16.

Nov 17, 2021 06:14 PM

Healthcare

Chinese Biopharma Company BeiGene Records USD 300 Mn Revenue in 2020

Over CNY 1 billion revenue of the original drug maker came from the PD-1 product.

Feb 26, 2021 04:47 PM

Briefing Dec 06, 2021 10:30 AM · Automotive | Technology | Healthcare

Yuan universe concept stocks rose and warmed up, and shuobaid rose more than 8%

Briefing Dec 06, 2021 10:19 AM · Technology | Healthcare

Hong Kong Pharmaceutical stocks continued to decline, and Qiming medical fell more than 14%

Briefing Dec 05, 2021 03:48 PM · Technology

Chenguang stationery: the controlling shareholder and the unanimous person intend to increase their holdings by RMB 100 million to RMB 500 million within three months

Healthcare

Chinese Biotech I-Mab Plans to Repurchase Stocks of USD 20 Mn

The Nasdaq-listed Chinese clinical-stage biopharmaceutical is taking action in response to the market undervaluation.

Jul 16, 2020 12:36 PM

Healthcare

Biotech BeiGene Declares Direct Offering of Close to USD 2.08 Billion

The Nasdaq-listed profit-losing Chinese biotech is seeking capital for R&D in its ongoing anti-cancer pipelines.

Jul 13, 2020 10:25 AM

Briefing Nov 30, 2021 07:19 PM · Technology | Healthcare

Jiahe Meikang: Online roadshow time: 14:00-17:00, December 2

Briefing Nov 26, 2021 09:48 PM · Healthcare

Baiji Shenzhou has reached strategic cooperation with JD health

Briefing Oct 08, 2021 07:24 AM · Real Estate | Healthcare

The effect of specific drugs is remarkable. Aviation stocks have a dual recovery logic. Analysts say they are at the bottom of the stock price and expectations

Briefing Sep 13, 2021 02:15 PM · Healthcare

Baiji Shenzhou welcomes the milestone of "going to sea" again, and PD-1 monoclonal antibody baizean ® The new drug marketing application for esophageal squamous cell carcinoma was accepted by FDA

EqualOcean Analysis

EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.

Address

Beijing 9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
Shanghai 2707-2708, AI Tower, 701 Yunjin Road, Xuhui Dc, Shanghai 200232, China

New York 404 5th Ave New York, NY, 10018, USA

About